2022 IADR/APR General Session
The 100 th General Session & Exhibition of the IADR was held in conjunction with the 5th Meeting of the Asia Pacific Region. The virtual meeting was attended by individuals from around the world. Those attending the meeting could choose from among 207 Interactive Talk sessions, seven Focused Learning Sessions, three Hands-on Workshops, five satellite symposia, 52 Symposia, one Distinguished Lecture Series and a plenary.The recordings in this library from the meeting are a selection of the science that was to be presented as part of the General Session. These recordings give you the opportunity to participate in the meeting and hear from leading researchers. The recordings include the IADR Distinguished Lecture Series speaker and symposia from a collection of scientific groups and networks.
This session can be purchased as part of the full meeting recordings within the product bundles
The International Association for Dental Research is an ADA CERP Recognized Provider. ADA CERP is a service of the American Dental Association to assist dental professionals in identifying quality providers of continuing dental education. ADA CERP does not approve or endorse individual courses or instructors, nor does it imply acceptance of credit hours by boards of dentistry. Concerns or complaints about a CE provider may be directed to the provider or to the Commission for Continuing Education Provider Recognition at ADA.org/CERP.
Session Description
Although non-surgical (steps 1 and 2) periodontal therapy is a necessary and effective treatment for periodontitis, in certain patients or sites this might not be sufficient to resolve inflammation and attain periodontal stability (i.e. no probing pocket depth ≥4 mm with bleeding on probing). This symposium will critically review the current limitations of non-surgical periodontal therapy and the main factors responsible for the variability in outcomes that can be observed in periodontitis patients. Moreover, based on the most recent knowledge on the pathogenesis of periodontitis, considering it an inflammatory disease secondary to dysbiosis, the rationale of using host modulators as adjuncts to step 2 periodontal therapy will be discussed. This represents a paradigm shift in the way we look at periodontitis treatment, since it opens to the idea of combining mechanical removal of bacterial deposits with the use of mediators of inflammation resolution.
In particular, the symposium will focus on the use of probiotics and mediators of inflammation resolution in step 2 periodontal treatment. In this context, indications will be provided to clinicians based on the S3-level treatment guideline recently published by the European Federation of Periodontology. Future perspectives for research will also be discussed.
Learning Objectives
Presentation Date
June 24, 2022
Presenters
Nikolaos Donos - Expected Outcomes and Limitations of Non-Surgical Periodontal Therapy
Eduardo Montero - The Use of Probiotics as an Adjunct to Non-Surgical Therapy
Hatice Hasturk - The Use of Mediators of Inflammation Resolution in Non-Surgical Therapy
Elena Calciolari - S3-Level EFP Treatment Guideline on Host Modulators and Future Perspectives
Sponsoring Groups/Networks
Microbiology/Immunology, Periodontal Research
CE Credits
1.5 Hours
Financial Interest Disclosure:
Professor Nikos Donos received research grants for preclinical and clinical research as well as support with biomaterials for research from Straumann, Geistlich, ITI, Osteology Foundation and BTI; he received lecturing fess from Geistlich, Straumann, Oral B, ITI, Osteology Foundation, Swiss society of Oral surgery, BSP webinars, Saudi Arabia society for periodontology, British dental association webinar, Oral B sponsored webinar; he received grants from UK charities and MRCDr Elena Calciolari received money as part of competitive research grants (either as a PI or CO-I) from Osteology Foundation, ITI, Geisltich, Academy of Osseointegration, BTI; she received consulting fees and webinar fees from Osteology FoundationDr Eduardo Montero has a patent without economic interest (merely intelectual property) of a probiotic formula marketed by AB-Biotics; he has received consulting fees and honoraria for lectures from Sunstar and AB-Biotics; his department (not himself) has received funding for 3 research projects on the use of probiotics in periodontology from Sunstar and AB-Biotics.No conflicts of interest declared by Professor Nagihan Bostanci Dr. Hatice Hasturk is inventor on several granted and pending licensed and unlicensed patents on lipid mediators awarded to the Forsyth Institute that are subject to consulting fees and royalty payments.
Although non-surgical (steps 1 and 2) periodontal therapy is a necessary and effective treatment for periodontitis, in certain patients or sites this might not be sufficient to resolve inflammation and attain periodontal stability (i.e. no probing pocket depth ≥4 mm with bleeding on probing). This symposium will critically review the current limitations of non-surgical periodontal therapy and the main factors responsible for the variability in outcomes that can be observed in periodontitis patients. Moreover, based on the most recent knowledge on the pathogenesis of periodontitis, considering it an inflammatory disease secondary to dysbiosis, the rationale of using host modulators as adjuncts to step 2 periodontal therapy will be discussed. This represents a paradigm shift in the way we look at periodontitis treatment, since it opens to the idea of combining mechanical removal of bacterial deposits with the use of mediators of inflammation resolution.
In particular, the symposium will focus on the use of probiotics and mediators of inflammation resolution in step 2 periodontal treatment. In this context, indications will be provided to clinicians based on the S3-level treatment guideline recently published by the European Federation of Periodontology. Future perspectives for research will also be discussed.
Learning Objectives
- Critically review the current limitations associated with non-surgical (steps 1 and 2) treatment of periodontitis
- Present the rationale and the current evidence behind the use of host modulators as adjunctive treatments to non-surgical (steps 1 and 2) periodontal therapy (particularly probiotics, omega-3 and mediators of inflammation resolution)
- Discuss the S3-level EFP treatment guideline on the treatment of periodontitis stage 1, 2 and 3 and future perspectives on the use of host modulators with an eye towards precision medicine.
Presentation Date
June 24, 2022
Presenters
Nikolaos Donos - Expected Outcomes and Limitations of Non-Surgical Periodontal Therapy
Eduardo Montero - The Use of Probiotics as an Adjunct to Non-Surgical Therapy
Hatice Hasturk - The Use of Mediators of Inflammation Resolution in Non-Surgical Therapy
Elena Calciolari - S3-Level EFP Treatment Guideline on Host Modulators and Future Perspectives
Sponsoring Groups/Networks
Microbiology/Immunology, Periodontal Research
CE Credits
1.5 Hours
Professor Nikos Donos received research grants for preclinical and clinical research as well as support with biomaterials for research from Straumann, Geistlich, ITI, Osteology Foundation and BTI; he received lecturing fess from Geistlich, Straumann, Oral B, ITI, Osteology Foundation, Swiss society of Oral surgery, BSP webinars, Saudi Arabia society for periodontology, British dental association webinar, Oral B sponsored webinar; he received grants from UK charities and MRCDr Elena Calciolari received money as part of competitive research grants (either as a PI or CO-I) from Osteology Foundation, ITI, Geisltich, Academy of Osseointegration, BTI; she received consulting fees and webinar fees from Osteology FoundationDr Eduardo Montero has a patent without economic interest (merely intelectual property) of a probiotic formula marketed by AB-Biotics; he has received consulting fees and honoraria for lectures from Sunstar and AB-Biotics; his department (not himself) has received funding for 3 research projects on the use of probiotics in periodontology from Sunstar and AB-Biotics.No conflicts of interest declared by Professor Nagihan Bostanci Dr. Hatice Hasturk is inventor on several granted and pending licensed and unlicensed patents on lipid mediators awarded to the Forsyth Institute that are subject to consulting fees and royalty payments.
Not eligible for individual purchase; must purchased as part of a meeting bundle.
